LOW-LEVEL LIGHT THERAPY (LLLT) or photobiomodulation.

Lideur mondiale dans étude de LLLT:

Michael R Hamblin Ph.D.

Associate Professor

Department of Dermatology

Harvard Medical School

BAR 414

Wellman Center for Photomedicine

Massachusetts General Hospital

40 Blossom Street

Boston MA 02114


Member of Affiliated Faculty of Harvard-MIT Division of Health Sciences and


Tel 617-726-6182

Fax 617-726-6643

e-mail hamblin@helix.mgh.harvard.edu

“Low level laser (light) therapy (LLLT) also known as photobiomodulation (PBM) therapy has been practiced for almost fifty years, and hundreds of positive clinical trials and thousands of laboratory studies have been published. Despite these impressive accomplishments LLLT has still not reached the stage of acceptance by mainstream medicine. The reasons for this were discussed at a recent Optical Society of America (OSA) Incubator meeting in Washington DC in 2014. Uncertainty about mechanisms was highlighted, and this paper will describe the current thinking. To drive LLLT towards mainstream medicine, we need better guidelines with standardized protocols and consistent parameters. Studies should be published in higher impact scientific and medical journals. Companies should avoid false promises and deceptive marketing, and physicians should receive a clearly defined return on investment with insurance reimbursement.”







He adviced me to use this model:


Laisser un commentaire